Compare Noble Corporation plc (NE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Recursion Pharmaceuticals Inc — how do they compare? Noble Corporation plc trades at $40.19 (market cap $6.73B), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Noble Corporation plc is far larger — about 3.1× Recursion Pharmaceuticals Inc's market cap, and Noble Corporation plc pays a 4.74% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Noble Corporation plc for 26 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NE | RXRX | |
|---|---|---|
Market Cap | $6.73B | $2.14B |
Volume | 1,027,635 | 30,789,535 |
Sector | Energy | Health |
52-Week High | $54.37 | $6.79 |
52-Week Low | $26.70 | $2.84 |
Typical Hold Time | 26 Days | 22 Days |
Enterprise Value | $8.16B | $1.66B |
Dividend Yield | 4.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $40.97, down 1.16% today, with a bearish technical outlook. The stock shows mixed earnings performance with recent misses but maintains positive cash flow. Analyst consensus is divided with a $52 price target suggesting 27% upside. Recent news includes a long-term drilling contract with Tullow in Ghana, extending utilization into 2027.
The outlook remains cautious due to ongoing legal investigations and volatile earnings. While valuation appears reasonable with EV/EBITDA of 8.79, declining revenue and profit margins pose challenges. The dividend provides income support, but investors face execution risks amid mixed analyst sentiment.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
